First-in-class Anti-tumor Agent ONC201 Induces Apoptosis in Hematological Malignancies with Wild Type and Mutant p53

survivors. Design: Retrospective study from 1992-2011. Setting: Data from Surveillance Epidemiology and End Results-13 registry. Patients: 15,517 FL patients. Main Outcome Measures: 1. Risk of SPM, developing 6 months after the diagnosis of FL, using Standardized Incidence Ratio (SIR) and Absolute Excess Risk (AER). 2. Poisson multivariate regression to study the impact of different variables on the risk of SPM. Results: At 71 months (range 5 -239 months) follow-up, 1766 patients (11.4%) developed SPM with SIR of 1.23 (95% CI 1.18-1.29; p